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ABSTRACT
ASSESSMENT OF NEUROTENSIN RECEPTOR AGONIST EFFECTS ON FEARPOTENTIATED STARTLE

By
Mark Aaron Vanden Avond
Systemic administration of the NTS1 receptor agonist PD149163 has exhibited anxiolytic
effects in male rats. The present study sought to further evaluate the potential anxiolytic
effects of PD149163 by assessing this compound in both male and female C57BL/J6
mice using the fear-potentiated startle (FPS) paradigm. Startle chambers were equipped
with a shock-grid floor, fluorescent light, and an acoustic startle speaker. Conditioning
took place between the light and floor shock, and test sessions measured startle to a 90
dB noise burst while the light was on (FPS) or off. Startle magnitude did not differ
between the male and female mice. PD149163 produced a significant difference between
male and female mice startle response and a significant reduction in FPS in females. The
NTS2 receptor agonist β-Lactotensin produced a sex difference at an intermediate dose.
The anxiolytic and partial 5-HT1A agonist buspirone did not produce a significant
difference in FPS. The reduction in FPS by PD149163 coincides with previous studies
conducted in male rats. The reduction in FPS found in female mice suggests that more
research is needed to examine the neurotensin system and sex differences. Overall, these
findings support targeting the neurotensin system for the development of novel strategies
for treating anxiety disorders.
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INTRODUCTION

Anxiety Disorders
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) defines anxiety as the exaggerated anticipation of a future threat and is associated with
muscle tension and preparation for future danger. While anxiety and fear are related, the
DSM-5 clarifies that fear is an emotional response to a real or perceived imminent threat
with autonomic arousal necessary for fight or flight, whereas anxiety is an exaggerated
response to a future threat (American Psychiatric Association, 2013). A substantial
amount of research shows that anxiety disorders can persist throughout one’s lifetime if
left untreated (Beesdo, Knappe, and Pine, 2009; Beesdo, Pine, Leib, and Wittchen, 2010;
Burstein, Beesdo-Baum, He, and Merikangas, 2014; Kessler, Andrade, Bijl, Demler, and
Stein, 2002; Kessler et al., 2005; Lieb, Becker, and Altamura, 2005; Mohr & Schneider
2013; Wittchen, 2002).
Separation anxiety disorder, selective mutism, specific phobia, social anxiety
disorder, panic disorder, agoraphobia and generalized anxiety are defined as anxiety
disorders in the DSM-5. While each anxiety disorder has a specific definition, there are
common symptoms among each disorder. These common symptoms are: a reaction that
is more intense, to a stimulus, event, or perceived stimulus, actively avoiding the
stimulus, event, or perceived stimulus, and occurs for six months or longer (American
Psychiatric Association, 2013).
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Anxiety disorders not only cause a burden on the individual, but also on society.
About forty-two percent of adults have or have had anxiety disorders and anxiety
disorders are the second highest prevalence for mental disorders (Kessler, Petukhove,
Sampson, Zaslavsky, and Wittchen, 2012; Lieb et al., 2005). Lieb et al. (2005) estimates
that generalized anxiety disorder costs around $250 per month for an individual, and
Eaton, Martins, Nestadt, Binevenu, Clarke, and Alexandre (2008) estimates around $11
billion per year for specific phobia. Anxiety can cause a decrease in work production and
quality of life, an increase in seeking medical practices, and impairment and disability
(Leib et al., 2005; Wittchen, 2002).
Anxiety disorders are more prevalent in women in their lifetime. In their
lifetimes, about thirty-three percent of women will be diagnosed with an anxiety disorder
compared to twenty-two percent of men (McLean, Asnaani, Litz, and Hofmann, 2011).
Girls have been shown to have rates of anxiety disorders twice that of boys at as early as
the age of six (Lewinsohn, Gotlib, Lewisohn, Seeley, and Allen, 1998). Women with
anxiety disorders are more likely than men to seek medical help and will miss more days
of work (McLean et al., 2011).
Neurocircuitry of Anxiety
The neurocircuity mediating anxiety involves complex interactions between a
number of structures, including the amygdala, septum, ventral tegmental area,
periaqueductal gray (PAG), hypothalamic-pituitary-adrenal axis, and the orbitofrontal
cortex.
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The amygdala, in particular, has long been considered a “fear center” in the brain.
In humans, higher amygdala volume is correlated with more anxiety (Qin, Young, Daun,
Chen, Supekar, and Menon, 2014). The amygdala mediates fear and anxiety in animal
behavioral models. The basolateral amygdala responds to cues that predict danger
(Amano, Duvarci, Popa, and Pare, 2011). The basolateral amygdala projects to the
central nucleus of the amygdala (Tye et al., 2011). Hitchcock & Davis (1986) found that
in male rats bilateral lesions of the central nucleus of the amygdala blocked the
potentiation of the startle reflex using a fear-potentiated startle paradigm in their
experiment. An external cue, which was previously combined with an aversive stimulus,
was used to produce an exaggerated startle response in the fear-potentiated startle
paradigm. In male rats, an electrolytic lesion of the pathway between the central nucleus
and the caudal lateral hypothalamus also blocked the fear-potentiated startle response,
providing further evidence that the amygdala is necessary. Moreover, the lateral
hypothalamus may play a role as well (Hitchcock & Davis, 1991). The central nucleus of
the amygdala also projects to the nucleus reticularis pontis caudalis (Rosen, Hitchcock,
Sananes, Miserenino and Davis, 1991). The nucleus reticularis pontis caudalis is
important for the production of the fear-potentiated startle response. Davis, Gendelman,
Tischler and Gendelman (1982) lesioned this area in male rats which abolished the
acoustic startle, and lesions more rostral, caudal or dorsal did not abolish the startle,
providing evidence that this area is important for the fear-potentiated startle response.
The septum is another important region in the production of anxiety-related
behaviors. The lateral septum has been shown to connects the amygdala to the
hypothalamus in a neural circuit implicated in anxiety-related behaviors (Calhoon & Tye,
3

2015). The elevated-plus maze is another behavioral test used to measure levels of
anxiety. Anxiety is assessed in an elevated-plus maze by recording the number of entries
and total time spent in open arms (i.e., those without walls) compared to closed arms of a
maze positioned at a certain height (e.g., 50 cm) above the floor. An increase in entries
and time spent in the open arm of the elevated-plus maze shows a decrease in anxietyrelated behavior. A group of male rats with the lateral septum lesioned showed an
increase in the percentage of open arm entries and percentage of time spent in the open
arm. Similar results were found in male rats with medial septal lesions (Menard & Treit,
1995).
The ventral tegmental area (VTA) in the midbrain is also important for stress and
anxiety-related behaviors. Quinpirole, a dopamine D2/3 agonist, administered into the
VTA has blocked fear-potentiated startle. Another study showed that lesions of the
medial ventral tegmentum also blocked fear-potentiated startle. These findings provide
evidence that dopamine neurons in the VTA are important for anxiety (Munro &
Kokkinidis, 1997; Borowski & Kokkinidis, 1996). Mukherjee et al. (2010) showed that
when circadian locomotor output cycles kaput (Clock) genes are deleted in mice, Clock-/mice had an increased firing rate of dopaminergic neurons in the VTA. The Clock-/- mice
showed lower anxiety behavior indicatd by increased time spent in the open arm of the
elevated-plus maze and time spent in the middle of an open field compared to wild-type
mice. These results suggests that there is less anxiety in the Clock-/- mice. Reduced
anxiety was no longer evident after Clock protein levels in the VTA of Clock-/- mice
returned to levels comparable to wild-type mice via viral-mediated gene transfer (Roybal
et al., 2007).
4

Lesions of the PAG before or after fear-conditioning training (light + shock
conditioning sessions) provided evidence that the PAG is implicated in the expression of
fear-potentiated startle response. Lesioning the PAG of male rats before or after training
inhibited potentiated startle caused by a light cue (Fendt, Koch, and Schnitzler, 1996).
Pharmacologically, intra-PAG infusion of the serotonin (5-HT)2B/2C receptor agonist,
meta-chlorophenylpiperazine (mCPP), decreased anxiety-like behavior in male mice
using the elevated-plus maze. Pretreatment of the 5-HT2A/2C receptor antagonist,
ketanserin, blocked the anxiolytic effects of mCPP which provides evidence that the 5HT2C receptor is important for anxiety in the PAG (Nunes-de-Souza, Nunes-de-Souza,
Rodgers, and Canto-de-Souza, 2008).
The hypothalamic-pituitary-adrenal axis mediates sympathetic nervous system
activity. The corticotrophin-releasing hormone neurons in the hypothalamus activate the
anterior pituitary gland. The pituitary gland, in turn, releases adrenocorticotropic
hormone, which causes the adrenal gland to release cortisol. The corticotrophin-releasing
hormone neurons in the hypothalamus are activated in preparation for an urgent situation.
Flandreau, Ressler, Owens, and Nemeroff (2011) have shown that a hyperactive
hypothalamic-pituitary-adrenal axis can cause behavior associated with anxiety. This
study examined Wistar rats using a battery of anxiety tests, including the open field test,
elevated plus maze, defensive withdrawal, and forced swim test and showed an increase
in adrenocorticotropic hormone concentrations.
The orbitofrontal cortex is important in processing reward and punishment, which
assigns value to stimuli. The medial orbitofrontal cortex examines the reward value of
stimuli, and the lateral orbitofrontal cortex examines the aversive properties of a stimulus
5

(for review, see Kringlebach and Rolls, (2004). Thus, the amygdala and orbitofrontal
cortex act together to assign fear memories to conditioned stimuli.
Common Pharmacological Treatments for Anxiety Disorders
Historically, barbiturates were some of the first drugs used to treat anxiety
(Lopez-Munoz, Ucha-Udabe and Alamo, 2005). Barbiturates bind to an allosteric site on
the GABAA receptor, causing a conformational change that increases chloride
conductance when the receptor is activated by an agonist (Sankar, 2012). Dixon, Rosahl
and Stephens (2008) used GABRA2 knockout mice, which are missing the genes that
encode the GABAA α2-subunit, and showed that pentobarbital hydrochloride did not have
any anxiolytic effects. This provides evidence that the GABAA α2-subunit is important
for the allosteric site that barbiturates bind to, and therefore is important for the anxiolytic
effects (i.e., anti-anxiety effects) of barbiturates. However, barbiturates have negative
effects. Barbiturates have a high abuse potential (Lopez-Munoz et al., 2005; McClane &
Martin, 1976) and a marginal therapeutic range during chronic use. Thus, chronic
barbiturates use can easily lead to overdose (Lopez-Munoz et al., 2005). Moreover,
barbiturates have been linked to many suicides (Gunnell & Eddleston, 2003).
Benzodiazepines were discovered in the 1960’s. Benzodiazepines, like
barbiturates, affect the GABA receptor (Sigel & Buhr, 1997). Like barbiturates,
benzodiazepines will bind an allosteric site on the GABAA receptor and increase the rate
of which Cl- channels open to increase chloride conductance (Sankar, 2012). The
benzodiazepine chlordiazepoxide increased the amount of entries to the open arm of the
elevated-plus maze in mice when compared to saline, providing evidence that
chlordiazepoxide decreases anxiety, which is also consistent with clinical evidence
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(Belzung, Le Guisquet, and Griebel, 2000). The benzodiazepine diazepam decreased
fear-potentiated startle in male mice (Risbrough, Brodkin, and Geyer, 2003) and
increased time spent in the open arms of an elevated plus maze (Cole & Rodgers, 1995).
Benzodiazepines replaced barbiturates for the treatment of anxiety disorders because the
risk of abuse potential is relatively lower compared to barbiturates (Smith & Rudolph,
2012). Benzodiazepines can cause sedation and cognitive deficits and long-term use can
lead to dependency and withdrawal symptoms (Durham, 2007; Glombok, Moodley, and
Lader, 1988). Also, benzodiazepines can cause psychomotor retardation, which can
produce slower reaction times that can impair driving skills and can cause anterograde
amnesia (Longo and Johnson, 2000).
Antidepressants were used in the 1960’s for the treatment of anxiety disorders.
The first antidepressants used for anxiety were monoamine oxidase inhibitors (MAOI),
but tricyclic (TCA) and serotonin reuptake inhibitor (SSRI) antidepressant drugs are
more widely used for long-term treatment of anxiety disorders (Sargant and Dally, 1962;
Durham, 2007). MAOIs increase monoamines in the synapse by inhibiting the enzyme
that breaks down the monoamines. TCAs increase synaptic serotonin and norepinephrine
by blocking the reuptake mechanism, along with binding to other receptors, such as the
histamine H1 receptor (Owens, Morgan, Plott, and Nemeroff, 1997). SSRIs are effective
by inhibiting the serotonin reuptake transport, which increases serotonin in the synapse.
MAOIs and TCAs are usually prescribed when SSRIs are not treating anxiety disorders
effectively, and are second- or third-line treatments due to their potential side effects.
(Sayed, Horn, and Murrough, 2014). For example, MAOIs interact with foods containing
tyramine, such as cheese and wines, and can lead to hypertension (Gardner, Shulman,
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Walker, and Tailor, 1996). Teixeira, Zangrossi, and Graeff (2000) showed that acute
administration of the antidepressant imipramine increased escape latencies, while chronic
imipramine reduced escape latencies in male rats. Similar acute effects were found using
sertraline, an SSRI. Sertraline increased startle in a fear-potentiated startle procedure,
which could be an indication of increased anxiety. Fluoxetine treatment did not show a
significant difference (Steiner, Lecourt, and Jenck, 2012). While efficacy for both
tricyclic antidepressants and SSRIs are similar, SSRIs are prescribed more frequently due
to their safety and tolerability (Zohar, 2000). Antidepressant drugs take a few weeks for
any therapeutic effects to occur. Along with delayed activation, antidepressant drugs are
only effective for about sixty percent of patients (Prus, 2014). This could be because
male rats given acute administration of fluoxetine, sertraline, and the 5-HT agonist mCPP
displayed decreased social interactions and increased self-grooming (Bagdy, Graf,
Anheuer, Modos, and Kantor, 2001). Decreasing social interactions between rats and
increasing self-grooming is an indication of high levels of anxiety.
Neurotensin
Neurotensin (NT) is a 13-amino-acid neuropeptide found in the central nervous
system and peripheral nervous system. As many other neuropeptides, NT acts as a
neuromodulator in the nervous system and is closely associated with dopamine systems
(St-Gelais, Jomphe, and Trudeau, 2006). In the VTA and substantia nigra NTS1 receptors
are expressed on about eighty to ninety-five percent of dopamine neurons (Binder,
Kinkead, Owens and Nemeroff, 2001; Dana et al., 1989). Dopamine neurons either
increase or decrease firing depending on the abundance of NT; high concentrations of NT
will increase dopamine firing while low concentrations of NT will decrease dopamine
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firing (Jiang, Pessia, and North, 1994; Farkas, Chien, Shigehiro and Nakajima, 1997; Wu
& Wang, 1995). NT utilizes three receptor iosforms, NTS1, NTS2 and NTS3/sortilin
receptors, and has the highest affinity for NTS1 receptors followed by NTS2 receptors.
The neurotensin receptors are g-protein coupled receptors (Luca et al, 2003), which
interact with dopamine receptors to decrease D2 receptor agonist binding affinity (Binder,
Kinkead, Owens, and Nemeroff, 2001).
The NTS1 receptor can be found throughout many brain areas, which corresponds
to evidnece that NT plays a role in anxiety, schizophrenia, drug abuse, neurodegenerative
diseases, pain, and many other disorders (St-Gelais et al., 2006; Prus, Hillhouse, and
LaCrosse, 2014). Boudin, Pelaprat, Rostene and Beaudet (1996) were the first to image
the NTS1 receptor in the whole mammalian brain using immunohistochemistry to identify
the receptor (see table 1). Of particular relevance to anxiety, NTS1 receptors were found
in the posterior cortical nucleus of the amygdala on perikarya, dendrites, and axon
terminals. The hippocampus also contains NTS1 receptors on cell bodies, dendrites, and
axon terminals. In the diencephalon, the thalamus and anterior dorsal nucleus found
perikarya labeled for NTS1 receptors. The hypothalamus contained NTS1 receptors on
axon terminals throughout the medial and lateral subdivisions and in the median
eminence.
Table 1: Neurotensin receptor locations
Brain area
Frontal Cortex: Layer II-III
Frontal Cortex: Layer IV
Frontal Cortex: Layer V
Parietal Cortex: Layer II-III

Dendrites

Perikarya/
Cell Body
+

+
+
+
9

Axon
+

Terminals

Parietal Cortex: Layer IV
Parietal Cortex: Layer V
Anterior Cingulate Cortex: Layer IV
Endopiriform Cortex: Layer IV
Insular Cortex: Layer IV
Perirhinal Cortex: LayerI-III and VI
Entorhinal Cortex
Retrosplenial Cortex: Layers I
Retrosplenial Cortex: Layers II-III
Caudate Putamen
Nucleus Accumbens: Core and Shell
Anterior Commissure
Islands of Calleja
Septum
Broca
Preoptic Nucleus
Bed Nucleus of the Stria Terminalis
Amygdala
Thalamus
Optic Tract
Hypothalamus
Suprachiasmatic Nucleus
Lateral Mammillary Nucleus
Subthalamus
Epithalamus
Habenula
Substantia Nigra
Pars Compacta
Ventral Tegmental Area
Interfascicular Nucleus
Nucleus Raphe Linearis Caudalis
Periaquductal Gray
Dorsal Raphe
Latrodorsal Tegmental Nuclei
Tegmentum
Locus Coeruleus
Tegmental Nucleus
Medulla
Pontine Nuclei
Reticular Formation
Inferior Olivary Nucleus
Paragigantocellular Nucleus
Vagus
Solitary Tract

+
+
+
+
+
+
+
+
+
+

+
+
+
+
+

+
+
+

+

+
+
+

+
+
+
+

+
+

+
+
+
+

+
+
+
+
+
+
+
+

+
+
+
+
+
+
+
+
+
+
+
+
+

+
+
+

+
+
+
+
+
+
+
+
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While NT is found throughout the brain and has different behavioral implications,
little has been studied with NT and differences between males and females. NT
expression is similar in male and female rats until puberty when sex hormones begin to
change NT levels (Bello et al., 2004; Ciofi, 2000). Ovariectomized female rats given
estradiol treatments expressed more NT when compared to ovariectomized female rats
that were not given estradiol treatments (Ciofi, 2000). However, Dufourny &
Warembourg (1999) did not find ovariectomized female guinea pigs to have a significant
change in NT immunoreactivity when subjects were given estradiol treatments. The
differences in NT expression post estradiol treatment could be due to species differences.
Mice could have a more similar NT system to primates than rats. In areas of the brain,
such as the subthalamic nucleus, mice and primates express NT mRNA while rats do not.
While rats did not have a NT containing neurons in some areas, rats also had neurotensin
containing neurons in areas where mice and humans did not. A neurotensin-dopamine
pathway projects to the prefrontal cortex, the nucleus accumbens and amygdala in rats,
but is not found in mice or humans (Smits, Terwisscha, van Scheltinga, van der Linden,
Burbach, and Smidt, 2004). NT concentrations were found to be different between males
and females in a number of brain regions, including: the prefrontal cortex, nucleus
accumbens, hippocampus, and substantia nigra. Due to the estrous cycle of female rats,
NT concentrations also vary in the VTA, nucleus accumbens, and anterior
caudate/putamen depending on where the female is during the cycle (Kinkead et al.,
2000).
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Neurotensin Pharmacological Agents in Anxiety Models
Few studies have examined the potential effects of NT on anxiety. Fitzpatrick et
al. (2012) have found that NTS1 receptor knockout male mice traveled less and spent less
time in the center using an open field test compared to wild-type controls. These effects
have been associated with higher levels of anxiety. However, a significant difference
was not found between the knockout mice and controls using an elevated plus maze.
These findings show that the ‘anxious’ phenotype of the knockout mice might be
dependent on the environment and context. Further research needs to examine the effects
that environment and NT has on anxiety. Ollmann et al. (2015) demonstrated an increase
in time spent in the open arms of an elevated plus maze after bilateral microinjections of
NT into the ventral pallidum in male rats showing an anxiolytic effect. PD149163, a NT1
receptor agonist, has been shown to decrease conditioned footshock-induced ultrasonic
vocalizations, which is an indication of anxiolytic effects (Prus et al., 2014). Shilling &
Feifel (2008) found that PD149163 reduced fear-potentiated startle in male rats, but also
decreased the startle magnitude. This suggests that PD149163 may produce unintended
effects, such as decreased locomotor activity, which could explain the decreased fearpotentiated startle effect. An even smaller amount of research has been conducted on the
pharmacology of the NTS2 receptor and the effects on anxiety. Male wild-type mice
were given β-lactotensin, a NTS2 receptor agonist, and time spent in the open arms of the
elevated plus maze increased (Hou et al., 2011). Further research needs to examine the
effects of NTS2 receptor agonists using other paradigms for anxiety.
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Fear-Potentiated Startle Paradigm
The fear-potentiated startle paradigm was first introduced in 1951 partly on the
anecdotal observation that patients with an anxiety disorder had an exaggerated startle
response to a sudden loud noise (Brown, Kalish, and Farber, 1951). Initially, rats were
conditioned using a light-buzzer conditioned stimulus (CS) presented for five seconds
with a unconditioned stimulus (UCS) shock initiating for the last two seconds of the CS.
It was believed that the CS-UCS pairing would lead to an anticipatory fear reaction. To
test this, a startle stimulus was presented in place of the shock and the magnitudes of the
jumps were recorded using a stabilimeter-like apparatus. The magnitudes of the jumps
were compared to a group that did not have the CS-UCS presented simultaneously, but
were presented the same amount of light-buzzer and shocks as the experimental group.
The experimental group produced a higher startle magnitude to a sudden sound when
compared to the control group (Brown et al., 1951).
Further studies have used pharmacological agents to study the effects on fearpotentiated startle. Extensive research has evaluated treatments that alter
neurotransmitters and their effects on potentiated startle (see table 2) (Cassella & Davis,
1985; Chi, 1965; Davis, 1979; Davis, 1986; Davis, Cassella, and Kehne, 1988; Davis,
Falls, Campeau, and Kim, 1993; Davis, Redmond, and Baraban, 1979; Hijzen & Slangen,
1989).
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Table 2: Effect of drugs on FPS

Drug

Receptor site

Agonist or
antagonist

Effects on
potentiate
d startle

Clonidine

α1 adrenergic

Agonist

Imipramine (acute

SERT & NET;
Histamine H1;
cholinergic
muscarinic
α2
adrenergic/histami
ne H1
β1 adrenergic

Reptake
inhibitor/antagon
ist

Blocked
Startle
No Effect

Piperoxane

Propranolol

Antagonist

Increase
Startle

Antagonist

Decrease
Startle
No Effect

WB4101 (2-(2,6α1 adrenoceptor
Dimethoxyphenoxyethyl)aminomet
hyl-1,4-benzodioxane
hydrochloride)
Yohimbine
α2 adrenoceptor

Antagonist

Amobarbital

GABAA

Positive
modulator

Diazepam

GABAA

DMCM ( methyl-6,7-dimethoxy-4ethyl-beta-carboline-3-carboxylate)
Flumazenil
Flurazepam

GABA

BZ site agonist
(positive
modulator for
GABAA)
Antagonist

Midazolam

GABAA

Nicotine

Cholinergic
Nicotinic

GABAA
GABAA
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Antagonist

Antagonist
BZ site agonist
(positive
modulator for
GABAA)
BZ site agonist
(positive
modulator for
GABAA)
Agonist

Increase
Startle
Blocked
Potentiatio
n
Blocked
Potentiatio
n
Increased
Startle
No Effect
Blocked
Potentiatio
n
Blocked
Potentiatio
n
Decreased
Startle

Scopolamine

Antagonist

No effect

Raclopride

Cholinergic
Muscarinic
Dopamine D2/3

Antagonist

SCH23390

Dopamine D1

Antagonist

SCH23390 + 8-OH-DPAT

Dopamine D1 +
Serotonin 5-HT1A

Antagonist +
Agonist

SCH23390 + Ipsapirone

Dopamine D1 +
Serotonin

Antagonist +
Partial Agonist

Cocaine

DAT/SERT/NET

Decreased
Startle
Decreased
Startle
Blocked
Potentiatio
n
Blocked
Potentiatio
n
Increase
Startle
Increase
Startle
Blocked
Potentiatio
n
No Effect
Blocked
Potentiatio
n
No Effect

d-amphetamine
Morphine

Reuptake
inhibitor
Dopamine releaser VMAT & DAT
blockers
Opioid Mu
Agonist
receptor

Naloxone
Buspirone

Opioid Mu
Serotonin 5-HT 1A

Antagonist
Partial Agonist

Cinanserin

Serotonin 5-HT

Antagonist

2A/2C

Cyproheptadine
Gepirone

Histamine H1
Serotonin 5-HT1A

Antagonist
Partial Agonist

Tropisetron

Serotonin 5-HT3

Antagonist

Ipsapirone

Serotonin 5-HT1A

Partial Agonist

Ketanserin

Serotonin 5HT2A/2B/2C
Serotonin 5-HT2C
α1 adrenoceptor

Antagonist

Ondansetron

Serotonin 5HT2B/2C & 5-HT1A
Serotonin 5-HT3

Antagonist &
Agonist
Antagonist

p-Chloroamphetamine
Fenclonine ( para-

Serotonin releaser
Serotonin depleter

m-CPP
MDL73005EF

Methysergide
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Agonist
Antagonist

No Effect
Blocked
Potentiatio
n
Decreased
Startle
Decreased
Startle
No Effect
No Effect
Blocked
Potentiatio
n
Decreased
Startle
Decreased
Startle
No Effect
Decreased

chlorophenylalanine)

Startle

Drugs that affect the adrenoceptors were shown to have different effects on
potentiated startle. Agonists, such as clonidine or propranolol, blocked potentiated
startle, while antagonists, such as piperoxan and yohimbine, increased potentiated startle.
Imipramine (acute and chronic) and WB4101, an agonist and antagonist respectively, had
no effects on potentiated startle (Davis et al., 1979; Davis et al., 1993; Cassella & Davis,
1985).
Drugs that facilitate GABA neurotransmission were found to inhibit potentiated
startle. Positive modulators of the GABA receptor, such as amobarbital, diazepam,
flurazepam and midazolam, blocked potentiated startle, while DMCM and flumazenil,
GABAA receptor antagonists, increased and had no effect on potentiated startle,
respectively (Chi, 1965; Davis, 1979; Davis et al., 1979; Davis et al., 1993; Hijzen &
Slangen, 1989).
Drugs that affect dopamine receptors have shown a differential effect. Dopamine
releasers, such as cocaine and d-amphetamine, increased potentiated startle, while
dopamine receptor antagonists, such as raclopride and SCH23390, decreased potentiated
startle. Dopamine receptor antagonists in combination with serotonin receptor agonists,
SCH23390 + 8-OH-DPAT, SCH23390 + ipsapirone, have blocked potentiated startle
(Davis et al., 1993; Borowski & Kikkindis, 1998).
Many drugs have been used to study the effects of the 5-HT receptor and their
effects on FPS. Partial agonists at 5-HT1A receptors, such as buspirone, gepirone, and
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ipsapirone, either block or decrease potentiated startle. Cinanserin, cyproheptadine and
ketanserin, all 5-HT receptor antagonists, had no effect potentiated startle, while other 5HT receptor antagonists, tropisetron, methysergide, ondansetron, and fenclonine,
decreased potentiated startle (Mansbach & Geyer, 1988; Davis et al., 1988; Davis et al.,
1993). The differential effects of the 5-HT receptor antagonists may be due to the
different receptor subtypes affected.
Lesion studies have identified structures important for FPS. Tischler & Davis
(1983) have found that lesions of the dorsal nucleus of the lateral geniculate nucleus,
deep layers of the superior colliculus, visual cortex, and posteroventral region of the
nucleus of the lateral lemniscus attenuated or eliminated potentiated startle, while lesions
to the pretectal nuclei, superficial layers of the superior colliculus, thalamic reticular
nucleus, nucleus reticularis pontis caudalis or dorsal nucleus of the lateral lemniscus did
not attenuate potentiated startle. Lesions of the amygdala blocked a potentiated startle
while lesions to the cerebellum or red nucleus did not (Hitchcock & Davis, 1986).
Lesions to the caudal ventral amygdalofugal pathway and substantia nigra blocked
potentiated startle, while lesions to the rostral ventral amygdalofugal pathway and 6OHDA lesions of substantia nigra did not block potentiated startle (Davis, 1986). With
the main “fear center” in the brain being the amygdala, Campeau & Davis (1995) showed
that lesions to the central nucleus and basolateral complex of the amygdala blocked
potentiated startle. When the hippocampus was lesioned freezing was attenuated, but
fear-potentiated startle was not affected (McNish, Gewirtz, and Davis, 1997). Thus,
lesion studies strongly implicate the amygdala as necessary for FPS.
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Most FPS research has involved rodents as test subjects; however, primates and
humans have also been studied and can exhibit a FPS response (Grillon & Davis, 1997).
Diazepam and morphine decrease potentiated startle in a dose-dependent manner in
rhesus monkeys, an effect previously found in rodents (Winslow, Nobel, and Davis,
2007). Norrholm et al. (2006) were the first to show within-session fear extinction and
reinstatement using startles in humans. This is important, because humans and nonhuman animals show similar physiological effects; there is a greater translational value in
studying when studying non-human animals. The next logical step would be to examine
how anti-anxiety drugs affect FPS in humans, and Patrick, Berthot, and Moore (1996)
showed that diazepam, a clinically used benzodiazepine, blocked potentiated startle, an
effect previously found in rodents and non-human primates (Davis et al., 1993). The FPS
paradigm was even used to test new types of drugs for clinical use. Grillon, Cordova
Levine Charles, and Morgan (2003) examined the effects of LY35470, a glutamate
receptor agonist, on FPS in humans, and found a reduction in potentiated startle along
with subjective data suggesting a decrease of overall anxiety levels. Hormones have also
been tested. Female participants were given injections of testosterone which reduced
potentiated startle. Hermans, Putman, Baas, Koppeschar, and van Honk (2006) were able
to study sex differences, and further supported the notions that testosterone mediates sex
differences in fears.
Given that clinically used anti-anxiety drugs, such as diazepiam and buspirone,
and lesion studies have shown to block or decrease potentiated startle, this gives the FPS
paradigm evidence for support to study anxiety. Further support in using the FPS
paradigm is the translational value between non-human animal test subjects and humans.
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Rationale
As mentioned previously, anxiety disorders are prevalent in society and are the
second most diagnosed mental disorders. Current treatments, benzodiazepines and
antidepressants, have considerable side effects. Benzodiazepines can be addictive and
can cause sedation and cognitive deficits. Antidepressants are effective in only about
sixty percent of people with an anxiety disorder and have many different side effects.
NTS1 receptor agonists have been shown to have a potential anxiolytic effect. Research
also suggests a role for the NTS2 receptor having anxiolytic effects (Hou et al., 2011).
The majority of behavioral studies using neurotensin drugs have been studied in male
rodents, which limits the translational value of research to humans. Using NTS1 and
NTS2 receptor agonists in male and female mice is the next logical step for advancing
exploration for treating anxiety.
Therefore, the present study was conducted to examine the NTS1 receptor agonist
PD149163, and the NTS2 agonist β-Lactotensin, on fear-potentiated startle in male and
female mice. We hypothesize that the NTS1 receptor agonist, PD149163, and the NTS2
receptor agoninst, β-Lactotensin, will significantly decrease FPS, buspirone, previously
shown to decrease FPS, will act as our positive control, and male and female mice will
have a different FPS and be affected differently with the drugs.

19

METHODS

Materials
Subjects
Forty-five male and 45 female wild-type C57/BL6 mice (Mus musculus) (Charles
River, Portage, MI) were used as subjects. Subjects were about two months old upon
arrival and weighted between 18 and 25 grams before drug tests. Animals were housed
three to a cage with food and water provided ad libitum. Animals were maintained in a
climate-controlled room with a 14/10-h light/dark cycle (lights on at 7.30). Behavioral
training and testing occurred two to three weeks after arrival and between 8.00 and 16.00.
Animal care and experiments were conducted in accordance with The Guide to Care and
Use of Laboratory Animals and was approved by the Institutional Animal Care and Use
Committee (protocol 254) at Northern Michigan University, Marquette, MI.
Test Compounds
PD149163 and β-lactotensin were generously provided by RTI International
(Piedmont, NC) and administered at doses of 0.1, 0.3 and 1.0 mg/kg (Carey, 2014; Hou et
al., 2011). Buspirone was purchased from Sigma-Aldrich (St. Louis, MO) and
administered at doses of 1.25, 2.5, and 5 mg/kg (Risbrough et al., 2003). The salt forms
of the drugs were used. All test compounds were dissolved in saline, and was
administered subcutaneously at a volume of 10 ml/kg 30-min prior to testing.
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Equipment
Two startle chambers were commercially built (Med Associates Inc., St. Albans,
VT) and consisted of a Plexiglas cage with steel rod floor bars. A scrambled current was
delivered to the steel rod floors to serve as footshocks. The cages rested on a platform
that transduced animal movements into digital recordings via the Startle Reflex software
(Med Associates Inc.). Florescent lights were placed next to the cages to serve as a
conditioned stimulus (see below). Speakers were placed alongside the cages and
produced a startle stimulus (0.20 sec, 90 dB, white noise burst) and a red light on the top.
The cages and other instruments were placed in sound-attenuated cabinets equipped with
fans for ventilation and masking noise. A computer controlled and recorded all data from
the startle chambers using Startle Reflex (Med Associates Inc.) in the experimental room.
The open-field consisted of two rectangular, open-top boxes (built from laminated
melamine). Each box measured 30 x 30 x 27cm. A camera was mounted 71cm from the
center of each box and recorded and analyzed locomotor activity using Noldus
EthoVision video software (Leesburg, VA). A lightbulb was placed 80cm from the
center of each box, providing light.
Procedure
Training
Training procedures were similar to those described by Risbrough et al. (2003).
The purpose of these conditioning trials was to pair the light (conditioned stimulus) with
the elicitation of shock (unconditioned stimulus). The expected result was that the
stimulus light (CS) will cause the mice to have a greater startle response (conditioned
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response) when the light is on. A conditioning session consisted of ten trials. A session
began with a 5-min acclimation period, consisting of a red chamber light and ventilation
fan turning on, but no experimental events. Following the acclimation period, ten trials
(separated by 120-180 sec) began and each trail consisted of a stimulus light activating
for 10 s and co-terminating with a 0.30 mA shock (0.25 sec duration) delivered to the
floor of the nonrestrictive cage (Figure 1a).
Testing
A series of drugs were tested in the mice, with N = 15 per group. One drug was
tested in each group, but mice within each group were tested with three doses of the test
drug, in addition to a saline test given before testing drug doses and a final saline test
given after testing drug doses. The three doses of each drug were tested in a counterbalanced, ascending order. For example, the test order for mouse FPS5 was saline,
PD149163 0.3 mg/kg, PD149163 1.0 mg/kg, PD149163 0.1 mg/kg, and saline. Test
sessions were separated by six to seven days. After a dose has been tested, one training
session was conducted the day prior to the next test session in order to maintain
conditioning with the light-shock pairing.
A testing session consisted of 24 trials. A session began the same as a training
session. Following the acclimation period, ten startle stimuli (0.20 sec, 90 dB, white
noise burst) separated by 20 s occurred in the dark to habituate the subject to the startle
burst before the light cue turned on. Then, 24 trials (separated by 120-180 sec) consisted
of either a stimulus light activated for 10 sec preceding the activation of a startle stimulus
or no stimulus light being activated for a ten sec period prior to a white noise burst. Half
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of the trials consisted of the light-startle stimulus pairing and half consisted of the startle
stimulus only (i.e., with no preceding stimulus light (Figure 1b).
Stimulus light on
a Training trials

0

Stimulus light off

9.80 10

130-190 sec

b Testing trials

0

9.80 10

130-190 sec

130-190 sec

Figure 1: Schematic description of stimulus presentation during training and test trials.
(a) Training trials. Ten training trials consisted of a ten sec light cue co-terminating with
a 0.30 mA scrambled footshock during the last 0.25 sec. A dark period followed the light
period which varied 120 to 180 sec. (b) Testing trials. Twenty-four trials consisted of a
stimulus light turning on for ten seconds and co-terminating with a 0.20 sec, 90 dB, white
noise burst startle stimulus, followed by a dark period of 120-190 sec. Twelve of the
trials consisted of the stimulus light on, while twelve trials consisted of the stimulus light
off.
Open-Field Test
Immediately following fear-potentiated startle tests, mice were placed in the
center of the open-field for five minutes. During this open-field session, total path-length
of movements, total time spent in the center of the box, and total number of times mice
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entered and left the center of the open field was measured. Following each trail, the
open-field was cleaned using isopropyl alcohol.
Data Analysis
The first ten startle stimuli of the test session were used to habituate the animals
to the startle stimulus and were not used in the data analysis. The dependent variables
measured for the FPS test sessions were FPS (+/- standard error of the mean [SEM]) and
mean startle magnitude (+/- SEM). The FPS was calculated as follows:
𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑙𝑖𝑔ℎ𝑡 𝑛𝑜𝑖𝑠𝑒 𝑡𝑟𝑖𝑎𝑙𝑠 − 𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑛𝑜𝑖𝑠𝑒 𝑜𝑛𝑙𝑦 𝑡𝑟𝑖𝑎𝑙𝑠
(
) ∗ 100
𝑠𝑡𝑎𝑟𝑡𝑙𝑒 𝑚𝑎𝑔𝑛𝑖𝑡𝑢𝑑𝑒 𝑓𝑜𝑟 𝑛𝑜𝑖𝑠𝑒 𝑜𝑛𝑙𝑦 𝑡𝑟𝑖𝑎𝑙𝑠

(Shilling & Feifel, 2008; Walker & Davis, 2002; Winslow, Nobel and Davis,
2007). This calculation provides the percentage of startle occurring from the difference
between the white noise burst when the stimulus light was on and off above the intensity
of startle occurring from the white noise burst when the stimulus light was off. The
dependent variable for the open field tests were total path length (cm) total time spent in
the center of the box (sec), and total number of times mice entered and left the center of
the open field. All dependent variables for the open field tests were reported as means
(+/- SEM).
As noted earlier, the subjects in all groups were treated with saline before and
after drug treatment. This allowed for a determination whether there was an increase or
decrease in FPS or startle magnitude after weeks of drug testing. The FPS for saline
before versus after drug testing were compared using a paired-samples t-test. A pairedsamples t-test was used to compare the startle magnitude during light-noise test trials and
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noise-only trials to see if potentiation did occur as a result of activating the light stimulus.
A two-factor mixed measures ANOVA was used, with sex as the between-subjects factor
and drug dose as the within-subjects factor for each group, to determine if there was a sex
difference and/or an interaction between sex and drug dose for FPS. Because it was also
of interest to determine the effects of each drug dose within each sex alone on FPS and
startle magnitude, a one-way repeated measure ANOVA was used to analyze the effects
of each dose on FPS and startle magnitude within each group of male or female subjects.
Any statistically significant differences were further analyzed using Bonferroni post hoc
tests.
Total distance traveled in the open field was analyzed using a one-way repeated
measure ANOVA for each group to assess if locomotor activity was also affected. Total
time spent in the center was assessed using a one-way repeated measure ANOVA for
each group. Total entries and exits from the center were analyzed using a one-way
repeated measure ANOVA. All statistical analyses were conducted using GraphPad
Prism version 6.0 (GraphPad Software, La Jolla, CA).

25

RESULTS

PD149163
There was no statistical difference in FPS between saline before (M=12.30,
SEM=3.79) and after (M=17.65, SEM=3.73) testing PD149163 in male mice, t(14)=0.99,
p=0.34 (data not shown). There was no statistical difference in percent FPS between
saline before (M=16.81, SEM=4.07) and after (M=12.67, SEM=4.35) testing PD149163
in female mice, t(14)=0.66, p=0.52 (data not shown).
The light-noise startle magnitude was compared to the noise only startle
magnitude for saline (i.e., the mean of saline values before and after testing PD149163)
in the male PD149163 group. There was a statistically significant increase in the startle
magnitude in the light-noise (M=965.7, SEM=61.72) condition compared to the noiseonly (M=803.8, SEM=49.32) condition for males, t(29)=5.83, p<0.0001 (Figure 2 top).
The light-noise and noise-only startle magnitude was also compared for saline in the
female PD149163 group. There was also a statistically significant increase in startle
magnitude in the light-noise (M=736.7, SEM=36.94) condition compared to the noiseonly (M=613.1, SEM=27.12) condition for female; t(29)=5.115, p<0.0001 (Figure 2
bottom).
A two-way mixed factor ANOVA for FPS between sex and dose of PD149163
revealed a statistically significant effect of dose, F(3,84)=6.84, p=0.0004, and sex,
F(1,28)=13.79, p=0.0009, but no interaction, F(3,84)=2.18, p=0.10 (Figure 3).
Bonferroni post hoc test confirmed that doses of 0.1 and 1.0 mg/kg for females
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significantly decreased when compared to males. Figure 4 (top) shows the FPS for saline
or PD149163 administration to male mice. PD149163 administration significantly
altered the FPS, F(2.35, 32.86)=3.56, p=0.034, in male mice. This was due to a
significant increase in FPS at the 0.1 (mg/kg) dose when compared to saline. Figure 4
(bottom) shows the FPS for saline or PD149163 administration to female mice.
PD149163 administration significantly altered the FPS, F(2,27.90)=5.22, p=0.01, in
female mice. This was due to a significant decrease in FPS at the 1.0 (mg/kg) dose when
compared to saline.
A two-way mixed factor ANOVA for startle magnitude between sex and lightnoise trials revealed a significant effect for dose, F(3,84)= 112.0, p<0.0001, sex, F(1,28)=
8.56, p=0.0067, and interaction, F(3,84)= 4.16, p=0.0085 (data not shown). Further
analysis showed saline an 0.1 mg/kg to be significantly decreased in females compared to
males. A two-way mixed factor ANOVA for startle magnitude between sex and noiseonly trials revealed a significant effect for dose, F(3,84)= 95.28, p<0.0001, sex, F(1,28)=
4.237, p=0.049, and interaction, F(3,84)= 4.14, p=0.0087 (data not shown). Further
analysis showed saline to be significantly decreased in females compared to males. A
one-way repeated measures ANOVA for startle magnitude during the light-noise trials
for male mice was significantly different across doses of PD149163; F(2.28,
31.92)=49.15, p<0.0001 (Figure 5 top). This was due to a significant decrease in startle
magnitude at the 0.3 and 1.0 (mg/kg) doses compared to saline. Startle magnitude during
the noise-only trials for male mice was also significantly different across doses of
PD149163; F(2.07, 29.00)=46.12, p<0.0001 (Figure 5 bottom). This was due to a
significant decrease in startle magnitude at the 0.1, 0.3, and 1.0 mg/kg doses compared to
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saline. Startle magnitude during the light-noise trials for female mice was significantly
different across doses of PD149163; F(2.54, 35.54)=93.50, p=0.0015 (Figure 6 top). This
was due to a significant decrease in mean startle magnitude at the 0.1, 0.3, and 1.0 mg/kg
doses compared to saline. Startle magnitude during the noise-only trials for female mice
was significantly different across doses of PD149163; F(2.57, 35.97)=60.64, p=0.0027
(Figure 6 bottom). This was due to a significant decrease in startle magnitude at the 0.1,
0.3, and 1.0 mg/kg doses compared to saline.
A two-way mixed factor ANOVA for total distance traveled (cm) between sex
and dose of PD149163 revealed a statistically significant effect of dose, F(5,140)=181.8,
p<0.0001, but neither sex [F(1,28)=0.26, p=0.62] nor the interaction, F(5,140)=1.40,
p=0.23. Figure 7 (top) shows the total distance traveled (cm) after saline or PD149163
administration to male mice. PD149163 administration significantly altered the total
distance traveled in male mice, F(2.33, 32.60)=150.0, p<0.0001. There was a significant
decrease in total distance traveled at doses of 0.1, 0.3, and 1.0 mg/kg when compared to
saline in male mice. Figure 7 (bottom) shows the total distance traveled (cm) after saline
or PD149163 administration to female mice. PD149163 administration significantly
altered the total distance traveled in female mice, F(3.17, 44.35)=61.99, p=0.0007. There
was a significant decrease in total distance traveled at doses of 0.1, 0.3, and 1.0 mg/kg
when compared to saline in female mice.
A two-way mixed factor ANOVA for total time (s) spent in center between sex
and dose of PD149163 revealed a statistically significant effect of dose, F(5,140)=16.92,
p<0.0001, and interaction, F(5,140)=4.26, p=0.0012, but not sex, F(1, 28)=3.80, p=0.06.
Further analysis revealed a significant decrease in total time spent in center for female
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mice when compared to male mice at the doses of 0.3 and 1.0 mg/kg. Figure 8 (top)
shows the total time spent in center (sec) after saline or PD149163 administration to male
mice. PD149163 administration did significantly alter the total time spent in center in
male mice, F(1.88, 26.41)=15.89, p=0.0018. This is due to an increase in total time spent
in the center at a dose of 1.0 mg/kg compared to saline in male mice. The total number of
entries and exits of the center area was significantly altered in male mice, F(2.49,
34.79)=21.74, p<0.0001 (Figure 9 top). This was due to a significant decrease at the 0.3
and 1.0 mg/kg doses. Figure 8 (bottom) shows the total time spent in center (sec) after
saline or PD149163 administration to female mice. PD149163 administration
significantly altered the time spent in center in female mice, F(1.93, 26.97)=5.95,
p=0.0078. This is due to an decrease in total time spent in the center at a dose of 0.3
mg/kg in female mice. The total number of entries and exits of the center area was
significantly altered in female mice, F(2.58, 36.15)=15.74, p<0.0001 (Figure 9 bottom).
This was due to a significant decrease at the 0.3 and 1.0 mg/kg doses.
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PD149163 Startle Magnitude: Saline

Figure 2: The light-noise and noise-only startle magnitude during saline administration
for the PD149163 group in male (top) and female (bottom) mice. ****p<0.0001
light+noise versus noise-only. Data are expressed as mean +/- SEM, N=15.
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Effects of PD149163 on FPS

Figure 3: The effect of PD149163 administration on FPS in male (square) and female
(circle) mice. Data are expressed as mean +/- SEM, N=15.
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Effects of PD149163 on FPS

*

Figure 4: The effect of PD149163 administration on FPS in male (top) and female
(bottom) mice. *p<0.05 versus saline. Data are expressed as mean +/- SEM, N=15.

32

PD149163 Startle Magnitude: Male Light-Noise and Noise-only
Light-Noise

Noise-only

Figure 5: The light-noise (top) and noise only (bottom) startle magnitude during
PD149163 administration compared to saline in male mice. *p<0.05 & ****p<0.0001
versus saline. Data are expressed as mean +/- SEM, N=15.
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PD149163 Startle Magnitude: Female Light-Noise and Noise-only
Light-Noise

Noise-only

Figure 6: The light-noise (top) and noise only (bottom) startle magnitude during
PD149163 administration compared to saline in female mice. *p<0.05 & ****p<0.0001
versus saline. Data are expressed as mean +/- SEM, N=15.
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PD149163: Distance Traveled

Figure 7: The effects of PD149163 on total distance traveled (cm) in the open field
apparatus in male (top) and female (bottom) mice. *p<0.05 & ****p<0.0001 versus
saline. Data are expressed as mean +/- SEM, N=15.

35

PD149163: Time Spent in the Center

Figure 8: The effects of PD149163 on the total time (s) spent in the center of the open
field apparatus compared to saline in male (top) and female (bottom) mice. *p<0.05 &
****p<0.0001 versus saline. Data are expressed as mean +/- SEM, N=15.
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PD149163: Total Entries and Exits of the Center

Figure 9: The effects of PD149163 on the total exits and entries of the center of the open
field apparatus compared to saline in male (top) and female (bottom) mice. **p<0.01,
***p<0.001 & ****p<0.0001 versus saline. Data are expressed as mean +/- SEM, N=15.
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β-Lactotensin
There was not a statistical difference in FPS between saline before (M=13.28,
SEM=2.67) and after (M=19.42, SEM=3.68) testing β-Lactotensin in male mice,
t(14)=1.61, p=0.13 (data not shown). There was not a statistical difference in FPS
between saline before (M=6.78, SEM=5.11) and after (M=16.62, SEM=3.14) testing βLactotensin in female mice, t(14)=1.65, p=0.12 (data not shown).
The light-noise startle magnitude was compared to the noise-only startle
magnitude for saline (i.e., the mean of saline values before and after testing βLactotensin) in the male β-Lactotensin group. There was a statistically significant
increase in the startle magnitude in the light-noise (M=1064, SEM=41.39) condition
compared to the noise-only (M=884.7, SEM=37.10) condition for males, t(29)=6.31,
p<0.0001 (Figure 10 top). The light-noise and noise-only startle magnitude for saline
was compared in the female β-Lactotensin group. There was also a statistically
significant increase in the startle magnitude in the light-noise (M=762, SEM=43.54)
condition compared to the noise-only (M=661.6, SEM=37.13) condition for female,
t(29)=4.07, p=0.0003 (Figure 10 bottom).
A two-way mixed factor ANOVA for FPS between sex and dose of β-Lactotensin
revealed a statistically significant effect of sex, F(1,28)=8.09, p=0.008, interaction,
F(3,84)=2.74, p=0.049, but not dose, F(3,84)=2.033, p=0.11 (Figure 11). A Bonferroni
post hoc test confirmed that the dose of 0.3 mg/kg for females significantly decreased
compared to males. Figure 12 (top) shows the FPS for saline or β-Lactotensin
administration to male mice. β-Lactotensin administration did not statistically
significantly alter the FPS in male mice, F(2.54, 35.49)=0.11, p=0.93. Figure 12
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(bottom) shows the FPS for saline or β-Lactotensin administration to female mice. βLactotensin administration significantly altered the FPS in female mice,
F(2.27,31.75)=3.75, p=0.03. The post hoc analysis did not identify doses that differed
statistically from saline.
A two-way mixed factor ANOVA for startle magnitude between sex and lightnoise trials revealed a significant effect for dose, F(3,84)= 3.401, p=0.0214, sex, F(1,28)=
20.39, p=0.0001, but no interaction, F(3,84)= 1.675, p=0.1786 (data not shown). Further
analysis showed saline, 0.1, 0.3, and 1.0 mg/kg to be significantly decreased in females
compared to males. A two-way mixed factor ANOVA for startle magnitude between sex
and noise-only trials revealed a significant effect for sex, F(1,28)= 14.83, p=0.0006, but
not for dose, F(3,84)= 2.239, p=0.0897, nor interaction, F(3,84)= 0.7623, p=0.5184 (data
not shown). Further analysis showed saline, 0.1 and 0.3 mg/kg to be significantly
decreased in females compared to males. A one-way repeated measure ANOVA for
startle magnitude during the light-noise trials for β-Lactotensin was not significantly
different in male mice across doses; F(2.23, 31.14)=1.05, p=0.37 (Figure 13 top). Startle
magnitude during the noise-only trials for β-Lactotensin was not significantly different in
male mice across doses; F(2.64, 36.96)=1.53, p=0.23 (Figure 13 bottom). Startle
magnitude during the light-noise trials for β-Lactotensin was significantly different in
female mice across doses; F(2.92, 40.90)=5.64, p=0.0027 (Figure 14 top). This was due
to a significant decrease in startle magnitude at the 0.3 mg/kg dose compared to saline.
Startle magnitude during the noise-only trials for β-Lactotensin was significantly
different in female mice across doses; F(2.65, 37.13)=7.69, p=0.0009 (Figure 14 bottom).
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This was due to a significant decrease in startle magnitude at the 0.1 mg/kg dose
compared to saline.
A two-way mixed factor ANOVA for total distance traveled (cm) between sex
and dose of β-Lactotensin revealed a statistically significant effect of dose,
F(5,140)=11.62, p<0.0001, but neither sex, F(1, 28)=0.004, p=0.95, nor the interaction,
F(5,140)=0.28, p=0.92. Figure 15 (top) shows the total distance traveled (cm) after saline
or β-Lactotensin administration to male mice. β-Lactotensin administration significantly
altered the total distance traveled in male mice, F(3.22, 45.02)=7.92, p=0.0002. A
significant decrease of total distance traveled was shown at doses of 0.1, 0.3 and 1.0
mg/kg compared to saline in male mice. Figure 15 (bottom) shows the total distance
traveled (cm) after saline or β-Lactotensin administration to female mice. β-Lactotensin
administration significantly altered the total distance traveled in female mice, F(2.78,
38.93)=4.75, p=0.0076. The post hoc analysis did not identify doses that differed
statistically from saline.
A two-way mixed factor ANOVA for total time (sec) spent in center between sex
and dose of β-Lactotensin revealed no statistically significant effect of dose,
F(5,140)=2.02, p=0.08, sex, F(1,28)=1.10, p=0.30, and interaction, F(5,140)=1.27,
p=0.28. Figure 16 (top) shows the total time spent in center (sec) after saline or βLactotensin administration to male mice. β-Lactotensin administration did not
significantly altered the total time spent in center in male mice, F(3.20, 44.75)=2.17,
p=0.10. The total number of entries and exits of the center area was not significantly
altered in male mice, F(2.70, 37.75)=0.61, p=0.60 (Figure 17 top). Figure 16 (bottom)
shows the total time spent in center (sec) after saline or β-Lactotensin administration to
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female mice. β-Lactotensin administration did not significantly altered the time spent in
center in female mice, F(2.97, 41.64)=1.26, p=0.29. The total number of entries and exits
of the center area was not significantly altered in female mice, F(2.15, 30.12)=1.64,
p=0.21 (Figure 17 bottom).
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β-Lactotensin Startle Magnitude: Saline

Figure 10: The light-noise and noise-only startle magnitude during saline administration
for the β-Lactotensin group in male (top) and female (bottom) mice. ***p<0.001 &
****p<0.0001 light+noise versus noise-only. Data are expressed as mean +/- SEM,
N=15.
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The Effects of β-Lactotensin on FPS

β-Lactotensin (mg/kg)
Figure 11: The effect of β-Lactotensin administration on FPS in male (square) and female
(circle) mice. Data are expressed as mean +/- SEM, N=15.
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The Effects of β-Lactotensin on FPS

β-Lactotensin (mg/kg)

Females

β-Lactotensin (mg/kg)
Figure 12: The effect of β-Lactotensin administration on percent fear-potentiated startle
in male (top) and female (bottom) mice. Data are expressed as mean +/- SEM, N=15.
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β-Lactotensin Statle Magnitude: Male Light-Noise and Noise-only

Light-Noise

β-Lactotensin (mg/kg)

Noise-only

β-Lactotensin (mg/kg)
Figure 13: The light-noise (top) and noise only (bottom) startle magnitude during βLactotensin administration compared to saline in male mice. Data are expressed as mean
+/- SEM, N=15.
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β-Lactotensin Statle Magnitude: Female Light-Noise and Noise-only

Light-Noise

β-Lactotensin (mg/kg)

Noise-only

β-Lactotensin (mg/kg)
Figure 14: The light-noise (top) and noise only (bottom) startle magnitude during βLactotensin administration compared to saline in female mice. *p<0.05 & **p<0.01
versus saline. Data are expressed as mean +/- SEM, N=15.
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β-lactotensin: Total Distance Traveled

β-Lactotensin (mg/kg)

β-Lactotensin (mg/kg)
Figure 15: The effects of β-lactotensin on the total distance traveled (cm) in the open
field apparatus in male (top) and female (bottom) mice. *p<0.05 & **<0.01 versus
saline. Data are expressed as mean +/- SEM, N=15.
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β-lactotensin: Time Spent in the Center

β-Lactotensin (mg/kg)

β-Lactotensin (mg/kg)
Figure 16: The effects of β-Lactotensin on the total time (s) spent in the center of the
open field apparatus compared to saline in male (top) and female (bottom) mice. *p<0.05
versus saline. Data are expressed as mean +/- SEM, N=15.
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β-lactotensin: Total Entries and Exits of the Center

β-Lactotensin (mg/kg)

β-Lactotensin (mg/kg)
Figure 17: The effects of β-Lactotensin on the total exits and entries of the center of the
open field apparatus compared to saline in male (top) and female (bottom) mice. Data
are expressed as mean +/- SEM, N=15.
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Buspirone
There was no statistical difference in FPS between saline before (M=19.10,
SEM=2.43) and after (M=21.88, SEM=4.15) testing buspirone in male mice, t(14)=0.50,
p=0.63. There was no statistical difference in FPS between saline before (M=21.18,
SEM=4.12) and after (M=21.7, SEM=4.23) testing buspirone in female mice, t(14)=0.02,
p=0.98.
The light-noise startle magnitude was compared to the noise-only startle
magnitude for saline (i.e., the mean of saline values before and after testing buspirone) in
the male buspirone group. There was a statistically significant increase in the startle
magnitude in the light-noise (M=1067, SEM=61.24) condition compared to the noiseonly (M=852.6, SEM=52.36) condition for males, t(29)=8.41, p<0.0001 (Figure 18 top).
The light-noise and noise-only startle magnitude for saline was also compared in the
female buspirone group. There was also a statistically significant increase in the startle
magnitude in the light-noise (M=718.6, SEM=41.82) condition compared to the noise
only (M=553.7, SEM=30.02) condition for female, t(29)=7.02, p<0.0001 (Figure 18
bottom).
A two-way mixed factor ANOVA for FPS between sex and dose of buspirone
revealed no statistically significant effect of dose, F(3,84)=0.71, p=0.55, sex,
F(1,28)=0.15, p=0.70, and interaction, F(3,84)=0.41, p=0.74 (Figure 19). Figure 20 (top)
shows the FPS for saline or buspirone administration to male mice. Buspirone
administration did not significantly alter the FPS in male mice, F(1.89, 26.47)=1.41,
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p=0.26. Figure 20 (bottom) shows the FPS for saline or buspirone administration to
female mice. Buspirone administration did not significantly altered the FPS,
F(2.75,38.51)=0.14, p=0.92, in female mice.
A two-way mixed factor ANOVA for startle magnitude between sex and lightnoise trials revealed a significant effect for dose, F(3,84)= 10.12, p<0.0001, sex, F(1,28)=
18.65, p=0.0002, but no interaction, F(3,84)= 1.139, p=0.3382 (data not shown). Further
analysis showed saline, 1.0, 2.5 and 5.0 mg/kg to be significantly decreased in females
compared to males. A two-way mixed factor ANOVA for startle magnitude between sex
and noise-only trials revealed a significant effect for dose, F(3,84)= 7.538 , p=0.0002,
sex, F(1,28)= 15.74, p=0.0003, but no interaction, F(3,84)= 0.4127, p=0.7443 (data not
shown). Further analysis showed saline, 1.0, 2.5 and 5.0 mg/kg to be significantly
decreased in females compared to males. A one-way repeated measure ANOVA for
startle magnitude during the light-noise trials for buspirone was significantly different in
male mice across doses, F(2.28, 31.86)=3.62, p=0.03 (Figure 21 top). This was due to a
significant decrease in startle magnitude at the dose of 5.0 mg/kg compared to saline.
Startle magnitude during the noise-only trials for buspirone was not significantly
different in male mice across doses; F(2.79, 39.01)=1.71, p=0.18 (Figure 21 bottom).
Startle magnitude during the light-noise trials for buspirone was significantly different in
female mice across doses; F(2.43, 34.06)=9.32, p=0.0003 (Figure 22 top). This was due
to a significant decrease in startle magnitude at the 2.5 and 5.0 mg/kg doses compared to
saline. Startle magnitude during the noise-only trials for buspirone was significantly
different in female mice across doses; F(2.45, 34.26)=11.61, p<0.0001 (Figure 22
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bottom). This was due to a significant decrease in startle magnitude at the 1.0, 2.5 and
5.0 mg/kg doses compared to saline.
A two-way mixed factor ANOVA for total distance traveled (cm) between sex
and dose of buspirone revealed a statistically significant effect of dose, F(5,140)=43.75,
p<0.0001, but neither sex, F(1,28)=0.06, p=0.81, nor the interaction, F(5,140)=0.89,
p=0.49. Figure 23 (top) shows the total distance traveled (cm) after saline or buspirone
administration to male mice. Buspirone administration significantly altered the total
distance traveled in male mice, F(3.19, 44.59)=27.77, p<0.0001. This was due to a
significant decrease in total distance traveled at the 1.0, 2.5 and 5.0 mg/kg doses in male
mice. Figure 23 (bottom) shows the total distance traveled (cm) after saline or buspirone
administration to female mice. Buspirone administration significantly altered the total
distance traveled in female mice, F(2.77, 38.83)=17.49, p<0.0001. This was due to a
significant decrease in total distance traveled at the 1.0, 2.5, and 5.0 mg/kg doses in
female mice.
A two-way mixed factor ANOVA for total time (sec) spent in center between sex
and dose of buspirone revealed a statistically significant effect of dose, F(5,140)=7.94,
p<0.0001, but neithor sex, F(1,28)=1.07, p=0.31, not the interaction, F(5,140)=0.89,
p=0.49. Figure 24 (top) shows the total time spent in center (sec) after saline or
buspirone administration to male mice. Buspirone administration significantly altered the
total time spent in center, F(3.14, 43.90)=8.92, p<0.0001, in male mice. This is due a
significant increase in time spent in the center for the 1.0, 2.5, and 5.0 mg/kg doses in
male mice. The total number of entries and exits of the center was significantly altered in
male mice, F(3.41, 47.67)=16.62, p<0.0001 (Figure 25 top). This was due to a
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significant decrease at the 1.0, 2.5 and 5.0 mg/kg doses. Figure 24 (bottom) shows the
total time spent in center (sec) after saline or buspirone administration to female mice.
Buspirone administration did not significantly altered the time spent in center, F(2.94,
41.17)=2.15, p=0.11, in female mice. The total number of entries and exits of the center
was significantly altered in female mice, F(2.54, 35.54)=5.84, p=0.0037 (Figure 25
bottom). This was due to a significant decrease at the 1.0 and 5.0 mg/kg doses.
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Buspirone Startle Magnitude: Saline

Figure 18: The light-noise and noise-only startle magnitude during saline administration
for the buspirone group in male (top) and female (bottom) mice. ****p<0.0001
light+noise versus noise-only. Data are expressed as mean +/- SEM, N=15.
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The Effects of buspirone on FPS

Figure 16: The effect of buspirone administration on FPS in male (square) and female
(circle) mice. Data are expressed as mean +/- SEM, N=15.
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The Effects of buspirone on FPS

Figure 17: The effect of buspirone administration on percent fear-potentiated startle in
male (top) and female (bottom) mice. Data are expressed as mean +/- SEM, N=15.
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Buspirone Startle Magnitude: Male Light-Noise and Noise-only

Light-Noise

Noise-only

Figure 18: The light-noise (top) and noise only (bottom) startle magnitude during
buspirone administration compared to saline in male mice. *p<0.05 versus saline. Data
are expressed as mean +/- SEM, N=15.
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Buspirone Startle Magnitude: Female Light-Noise and Noise-only
Light-Noise

Noise-only

Figure 19: The light-noise (top) and noise only (bottom) startle magnitude during βLactotensin administration compared to saline in female mice. *p<0.05, **p<0.01 &
****p<0.0001 versus saline. Data are expressed as mean +/- SEM, N=15.
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Buspirone: Total Distance Traveled

Figure 20: The effects of buspirone on the total distance traveled in male (top) and female
(bottom) mice. **p<0.01, ***p<0.001 & ****p<0.0001 versus saline. Data are
expressed as mean +/- SEM, N=15.
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Buspirone: Time Spent in the Center

Figure 21: The effects of buspirone on the total time (s) spent in the center of the open
field apparatus in male (top) and female (bottom) mice. *p<0.05 & **p<0.01 versus
saline. Data are expressed as mean +/- SEM, N=15.

60

Buspirone: Total Entires and Exits of the Center

Figure 22: The effects of buspirone on the total exits and entries of the center of the open
field apparatus compared to saline in male (top) and female (bottom) mice. *p<0.05,
**p<0.01 & ***p<0.001 versus saline. Data are expressed as mean +/- SEM, N=15.

61

DISCUSSION

This was the first study to examine PD149163 and β-Lactotensin in male and
female mice using a fear-potentiated startle paradigm. The present study demonstrated
the differential effects of PD149163, a NTS1 agonist, β-Lactotensin, a NTS2 agonist, and
buspirone, an anxiolytic and partial 5-HT1A agonist, on FPS, startle magnitude, in male
and female mice. PD149163 did not decrease, but rather increased FPS in male mice.
Female mice, however, showed a decrease in FPS at the highest dose of PD149163. βLactotensin, at the doses tested, did not statistically increase or decrease FPS, however
there was a significant decrease in female mice at the 0.3 mg/kg dose compared to male
mice. Finally, there were no significant differences found in percent FPS using
buspirone.
We examined the effect of multiple treatments in male and female mice, by
testing saline before and after drug treatment and found no significant decrease in FPS for
any group. This indicates that habituation did not occur over time, and suggests that any
decreases in FPS occurred due to treatment. This may have been due to the training
session 24 hours prior to each test session and gives support for a repeated measures
design in order to study FPS. Winslow et al. (2007) also used a within subjects to study
FPS in monkeys. Rhesus monkeys developed a persistent increase of the startle response
when the CS was on during test sessions. A training session was completed prior to each
test session also.
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A significant increase in FPS in the PD14963 male group was found at the 0.1
mg/kg dose. We further examine this effect and looked at the differences between the
light-noise and noise-only startle magnitude. When comparing the different trials, the
light-noise trials decreased in startle magnitude but not enough to be considered different
from saline and the noise-only trials decreased enough to be considered different from
saline. This may indicate that PD149163 did not have an effect (or as strong of an effect)
on the cue light, but decreased the sensitivity of the subject more during the noise only
trials. The increase in FPS is contradictory to previous research. Shilling & Feifel (2008)
found a decrease in FPS following administration of PD149163 in rats. Although
PD149163 has been shown to decrease total distance traveled in mice, the decrease in
locomotor activity was not thought to be a factor for the increase in FPS in male mice
(Vadnie et al., 2014). In fact, one would hypothesize to see a decrease in FPS if
locomotor activity also decreased. Time spent in the center and entries and exits of the
center was not affected, therefore the subject was not trying to avoid the center which
would be an indicator of an anxiolytic effect. Given the decrease in locomotor data, and
no effect on time spent in the center and total entries and exits of the center, one would
predict a decrease in FPS, however the opposite was found.
Females expressed a decrease in FPS after a dose of 1.0 mg/kg of PD149163.
Both the light-noise and noise-only startle magnitude were decreased. The startle
magnitudes were similar to that of a dummy weight in the chamber, meaning that the
animals were not startling as much when the noise was produced regardless of the light
being on or off. Female locomotor activity and entries and exits of the center were
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decreased at the high dose. A possible reason for why the females showed a decrease in
the FPS was due to a decrease in locomotor activity.
NTS1 receptor knockout male mice traveled less and spent less time in the center
of an open field compared to wild-type controls (Fitzpatick et al., 2012). While the male
mice FPS data are contradictory to previous research, the female mice showed similar
effects found by administration of PD149163. A decrease in FPS and startle magnitude
following administration of PD149163 was previously found in rats (Shilling & Feifel,
2008). Vadnie et al. (2014) found a decrease in locomotor activity following injections
of PD149163 in mice. Our study further supports that PD149163, at higher doses,
disrupts general behavior.
β-Lactotensin decreased females FPS when compared to males at the 0.3 mg/kg
dose. We further examined this effect by looking at the startle magnitudes for light-noise
and noise-only trials. The light-noise startle magnitude was significantly decreased after
administration of the 0.3 mg/kg dose of β-Lactotensin, while the noise-only startle
magnitude was not affected. The locomotor activity, time spent in the center, and
number of entries and exits of the center did not increase or decrease, therefore locomotor
inhibition alone cannot explain the decrease in FPS at the 0.3 mg/kg dose. Baseline
acoustic startle was not different between NTS1 and NTS2 knockout and wild-type mice,
and showed that different drugs affected pre-pulse inhibition differently in NTS1 and
NTS2 knockout mice (Oliveros et al., 2010). This lends support to continue studying the
differences between NTS1 and NTS2 receptor agonists and antagonists.
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Previous research indicated that buspirone blocked FPS in rats (Kehne, Cassella,
and Davis, 1988; Risbrough et al., 2003). Our study found buspirone did not affect FPS
in either male or female mice. This could be due to the way the subjects were trained.
Moderate shocks produced enhanced startle amplitudes, while higher intensity shocks
produced lower startle amplitudes (Walker et al., 1997). In rats, 0.4 mA produced the
biggest difference between light-noise and noise-only conditions with a decrease in
startle amplitude and FPS at higher intensities. Our study used 0.3 mA and pilot data
showed an increase of a 30-40 percent FPS (unpublished).
Male and female rat NT mRNA expression and NT immunoreactivity is similar
until the fifth week of postnatal life. This is when the sexual dimorphism of NT
expression is established due to the presence sex hormone levels (Bello et al., 2004). NT
mRNA expression and NT immunoreactivity in female rats are different than males, and
the levels fluctuate during the estrous cycle (Kinkead et al., 2000). Further, estrogen has
been shown to enhance NT/neuromedin gene expression (Watters & Dorsa, 1998). NT
immunoreactive levels oscillate during the estrous cycle and are high during diestrus and
low during estrous (Bello et al., 1999). Hiroi and Neumaier (2005) showed that
injections of estrogen in ovariectomized female rats increased fear potentiated startle
when compared to ovariectomized females without injections of estrogen. Perhaps the
estrous cycle had an interaction with the drugs. Future research may want to control the
estrous cycle by using ovariectomized female mice.
NTS1 expression has been found in a variety of human tumors; Ewing’s sarcoma,
meningioma, astrocytoma, medullablastoma, and medullary thyroid cancers had the
highest incidence percent (above 25 percent) (Reubi, Waser Schaer, and Laissue, 1999).
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NTS1 agonists may simulate tumor growth in lung, pancreatic, colon, prostate, and breast
cancer, and NTS1 antagonists may inhibit tumor growth in these cancers (For review see:
Carraway & Plona, 2006). Further support shows that SR48692, a neurotensin receptor
antagonist, inhibits the growth of small cell lung cancer cells (Moody, Chiles, Casibang,
Moody, Chan, and Davis, 2001). While NTS1 is associated with progressing tumor and
cancer growth, the NTS2 receptor has not been implicated in cancer progression (Leyton,
Garcia-Marin, Jensen, and Moody, 2002). With the decrease at the 0.3 mg/kg dose of βLactotensin, further research may want to examine the effects of a more selective NTS2
receptor agonist or antagonist may have on anxiety.
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or Instruction

Project Title (If using external funds, enter the title used on the grant application): The
Effects of Neurotensin on the Expression of Fear-Potentiated Startle in Mice
Shaded area for IACUC use only.
General Instructions
Please check the IACUC website to ensure
Application Number:
254 Amended
you are using the current version of the form.
Date Application Received: November 2, 2015
All parts of this form must be submitted
electronically to the Institutional Animal Care
☒Approved ☐ Denied on November 9, 2015
and Use Committee (email:
IACUC@nmu.edu) and the relevant
Department Head or other departmental designee. Review of this application will
commence upon receiving the electronic application, but the project may not begin
until all required approval signatures are obtained via Right Signature. Please contact
the IACUC chair (email: IACUCChr@nmu.edu) if you have any questions.
Review Dates:
Designated Member Review of applications (appropriate for USDA Use Categories B and
C) will be completed within two weeks after receipt of the electronic application.
Full Committee Review of applications will take place on the last Friday of every month.
Applications for Full Committee Review must be electronically received by the first Friday of
the month. Full Committee Review is required for applications that fall under USDA Use
Categories D and E. Applications that fall under USDA Use Categories B and C will receive
Full Committee Review if requested by an IACUC member. Detailed procedures on the
IACUC review processes are located at the IACUC website.
I. Principal Investigator (Must be a faculty member or Department Head): Adam Prus
Co- Investigator: Mark Vanden Avond
Department: Psychology
Phone number: x2941
II. Funding Sources/Course Information and Dates
If the proposed work is for a course, please include the number of the course and
title of the course
Assessment of fear potentiated startle in mice
Funding Sources (External & Internal, if applicable) Internal?
Additional Funding Pending (click on the correct box)?

☒Yes

☐No

Project/Course Start Date: January 5, 2015
End Date (three year maximum): 1/5/2017
This application is (check one) ☒New
☒ Modification of an application
currently approved by the
Institutional Animal Care and Use Committee (a new protocol must be submitted after
three years)
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